Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 40,000 | reported | 22 Jan 2007 | tx 49+376,237−212,474 |
| CytoDyn Inc. | 0 | reported | 10 Jan 2019 | tx 83+16,164,237−8,983,723 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 10 Jan 2019 | OTHER | CytoDyn Inc. | 50,000 | — | deriv |
| 10 Jan 2019 | GRANT_AWARD | CytoDyn Inc. | 50,000 | — | deriv |
| 10 Jan 2019 | OTHER | CytoDyn Inc. | 100,000 | — | deriv |
| 10 Jan 2019 | GRANT_AWARD | CytoDyn Inc. | 100,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 2,093,972 | — | |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 200,000 | — | |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 26,000 | — | |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 62,136 | — | |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 25,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 250,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 50,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 100,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 50,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 200,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 333,333 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 333,333 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 1,333,334 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 950,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 50,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 128,530 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 450,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 550,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 50,000 | — | deriv |
| 16 Nov 2018 | GRANT_AWARD | CytoDyn Inc. | 11,543 | — | deriv |
| 16 Nov 2018 | OTHER | CytoDyn Inc. | 62,136 | — |
1 purchase reported after at least 12 months of silence — most recent on 30 Oct 2014.